Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Price
Target price
€293.50

€293.50

0.910%
2.65
0.910%
€315.70

€315.70

 
Latest predictions
€300.00
26.02.20
buy
€315.70
13.07.19
buy
€315.70
01.02.19
buy
€343.44
07.01.19
buy
€460.47
18.07.18
buy
€400.00
27.11.17
buy
Your prediction

Illumina Inc. Stock

Illumina Inc. gained 0.910% compared to yesterday.
Illumina Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
As a result the target price of €315.00 shows a slightly positive potential of 7.325% compared to the current price of €293.50 for Illumina Inc..

Pros and Cons of Illumina Inc. in the next few years

Pros
?
Market Position
?
Brand
?
Non-cyclic/Cyclic
Cons
?
Growth compared to competition
?
Future proof business model
?
Conscious of the environment
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Buy Illumina Inc.

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Illumina Inc. Stock

Trading Illumina Inc.

Trading Illumina Inc.

New thread Forum

News

Illumina to Webcast Upcoming Investor Conference Presentation


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.



UBS Genomics 2.0 and

Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome


Illumina, Inc. (Nasdaq:ILMN). The power to make bigger discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent Kit. The new NovaSeq 6000 v1.5 Reagent Kits aim to make whole genome

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020


Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.



Second quarter 2020 results reflect the impact of the global COVID-19 pandemic:

Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020


Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.



On the same day, at 2:00 pm Pacific

Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases


Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups


Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs

Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale


Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that

Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies


Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI

Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test


Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use

Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research


Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in

Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development: https://mms.businesswire.com/media/20200504005731/en/789307/5/AlexAravanis.jpg
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development


Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development

Illumina Reports Financial Results for First Quarter of Fiscal Year 2020


Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.



First quarter 2020 results:




  • Revenue of $859 million, a 2% increase compared to

Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance


Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation

Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19


Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using

Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020


Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.



Subject to quarter-end closing adjustments, the Company

Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.


Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products. The complaint was filed against BGI Genomics Co., Ltd

Illumina to Webcast Upcoming Investor Conference Presentations


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.



SVB Leerink Global